Global Liver Institute
GLOBAL LIVER INSTITUTE
As the field of NASH is on the verge of clinical and diagnostic breakthroughs, discover how GLI is promoting healthier living through our personalized nutrition solution, advocating for greater inclusion in clinical trials, and recognizing the role of drug safety and efficacy.
The 6th International NASH Day was a resounding global success, with over 100 partners from 55 countries participating.
GLI to Address Need for NAFLD/NASH Nomenclature Implementation Plan Since the joint medical...
Growth in Patient and Medical Community Engagement in NASH Community Persists Despite Recent Regulatory Disappointment
Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most common liver disease in the world – nonalcoholic fatty liver disease (NAFLD) – and it’s more severe form, nonalcoholic steatohepatitis (NASH).
How do you plan to #StepUpforNASH? Learn more about how you can get involved today!
Global Liver Institute Frustrated by FDA GIDAC Committee Failure to Recognize Serious, Unmet Need of Liver Patients in Rejection of Obeticholic Acid for Pre-Cirrhotic Fibrosis Due to NASH
Despite acknowledging OCA met the endpoint established by the FDA of reducing fibrosis by at least one stage, GIDAC voted against approval for treatment for NASH.